Zobrazeno 1 - 10
of 16
pro vyhledávání: '"J Leon-Villar"'
Autor:
MA Carvajal-Sanchez, MD Najera-Perez, P Pacheco-Lopez, J Ibañez-Caturla, L Fructuoso-Gonzalez, P Torrano-Belmonte, JA Gutierrez-Sanchez, M Hernandez-Sanchez, A Bolufer-Perez, J Plaza-Aniorte, J Leon-Villar
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb32a82a96d3340c6927dc90dde4a1bf
https://doi.org/10.1136/ejhpharm-2022-eahp.84
https://doi.org/10.1136/ejhpharm-2022-eahp.84
Autor:
MA Carvajal-Sanchez, A Machado-Leon, J Leon-Villar, P Pacheco-Lopez, J Ibañez-Caturla, L Fructuoso-Gonzalez, P Torrano-Belmonte, M Hernandez-Sanchez, JA Gutierrez-Sanchez, J Plaza-Aniorte
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2672596952156767476bed818e32717
https://doi.org/10.1136/ejhpharm-2022-eahp.92
https://doi.org/10.1136/ejhpharm-2022-eahp.92
Autor:
J Plaza-Aniorte, M Soria-Soto, J Leon-Villar, I Gorostiza-Frias, JC Titos-Arcos, A Espuny-Miró, T Alonso-Dominguez, P Selvi-Sabater, MM Sanchez-Catalicio, N Manresa-Ramón
Publikováno v:
Other hospital pharmacy topics.
Background Lenalidomide is one of the main drugs for the treatment of multiple myeloma, which has a high cost per patient. Purpose To describe and analyse the use of lenalidomide in multiple myeloma. Material and methods This retrospective study cove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74d15b1c838f0f1704c902b63e34514f
https://doi.org/10.1136/ejhpharm-2017-000640.415
https://doi.org/10.1136/ejhpharm-2017-000640.415
Autor:
A Aranda-Garcia, N Manresa-Ramón, A Espuny-Miró, M Soria-Soto, I Gorostiza-Frias, MM Sanchez-Catalicio, J Leon-Villar, JC Titos-Arcos, P Selvi-Sabater, T Alonso-Dominguez
Publikováno v:
Clinical pharmacy.
Background Orphan drugs mean a high economic impact and cost per patient, and in the past years there has been an increase in the number of patients. Purpose To describe and analyse the evolution of spending on orphan drugs based on diagnosis. Materi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6d45d07184e11c1d3a5e2a003fd926a
https://doi.org/10.1136/ejhpharm-2017-000640.127
https://doi.org/10.1136/ejhpharm-2017-000640.127
Autor:
I Sánchez-Martinez, M Soria-Soto, I Gorostiza-Frias, MT Alonso-Dominguez, P Selvi-Sabater, N Manresa-Ramón, AM Rizo-Cerdá, J Leon-Villar, Najera-Perez, N Bejar-Riquelme
Publikováno v:
European Journal of Hospital Pharmacy. 23:A69.2-A70
Background With the advent of new treatments for hepatitis C, we have achieved high cure rates, although this entails a significant increase in drug spending. Purpose To describe and analyse spending on HCV treatment in 2015. Material and methods Dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2e4aa072225d6ee751492cc1c3db41f
https://doi.org/10.1136/ejhpharm-2016-000875.157
https://doi.org/10.1136/ejhpharm-2016-000875.157
Autor:
J Leon-Villar, P Selvi-Sabater, N Manresa-Ramón, A. Mulet Alberola, N Bejar-Riquelme, T Alonso-Dominguez, A Campo-Soria, I Gorostiza-Frias, R Guerrero-Bautista, I Sánchez-Martinez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A173.2-A173
Background The ambulatory dispensation area is one of the most important sections of the hospital pharmacy. Treatment of several pathologies, such as oncology disease, hepatitis C virus, human immunodeficiency virus and more, are dispensed in this ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9f9c8164a9eef24eb74e39423188432
https://doi.org/10.1136/ejhpharm-2016-000875.392
https://doi.org/10.1136/ejhpharm-2016-000875.392
Autor:
P Selvi-Sabater, J Leon-Villar, JC Titos-Arcos, B Arribas-Díaz, N Manresa-Ramón, AM Rizo-Cerdá, MC Sanchez-Mulero, A Bosó-Ribelles, I Sánchez-Martinez, A Morego-Soler
Publikováno v:
European Journal of Hospital Pharmacy. 20:A112.1-A112
Background Bendamustine is approved in Spain for the treatment of chronic lymphocytic leukaemia (CLL), Non Hodgkin Lymphoma (NHL) and multiple myeloma (MM). The most frequent adverse reactions are haematological. Usually patients require supportive t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0a376c701d7e2ca80a2c6ecfbffa544
https://doi.org/10.1136/ejhpharm-2013-000276.311
https://doi.org/10.1136/ejhpharm-2013-000276.311
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.